Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Open-market sale Director sold 12,196 shares at an average $24.80 ($302,455)
  2. 4 Open-market sale Director sold 2,200 shares at $24.78 ($54,511)
  3. 4 Open-market sale Director sold 13,592 shares at an average $24.80 ($337,045)
  4. 4 Open-market sale Atillasoy Ercem sold 1,514 shares at $24.23 ($36,690)
  5. 4 Open-market sale Chief Medical Officer sold 18,689 shares at an average $23.91 ($446,862)
  6. 4 Open-market sale Chief Commercial Officer sold 16,584 shares at an average $25.14 ($416,906)
  7. 4 Open-market sale Chief Medical Officer sold 3,750 shares at $24.12 ($90,432)
  8. 4 Open-market sale Chief Commercial Officer sold 53,051 shares at an average $26.57 ($1,409,646)
  9. 4 Open-market sale Chief Medical Officer sold 40,548 shares at an average $22.11 ($896,685)
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Gift Director gave 818,663 shares (gift)
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Grant or award Chief Executive Officer acquired 200,000 shares (grant or award)
  18. 4 Open-market sale Chief Scientific Officer sold 150,000 shares at $22.75 ($3,412,500)
  19. 4 Open-market sale Chief Medical Officer sold 3,750 shares at $25.97 ($97,394)
  20. 4 Open-market sale Chief Scientific Officer sold 3,025 shares at $30.00 ($90,751)

Page 14 of 19 · 363 filings